Timolol Maleate: Clinical Overview
Indications
Timolol maleate ophthalmic solution is indicated for reducing intraocular pressure (IOP) in patients with open-angle glaucoma and ocular hypertension. 1, 2
Dosing Regimens
The standard dosing is 0.5% timolol maleate solution once daily in the morning, which provides equivalent IOP reduction to twice-daily dosing with better tolerability. 3
- 0.5% concentration provides maximal ocular hypotensive effect and is the preferred strength 4
- Once-daily morning dosing achieves 25-29% IOP reduction at peak and 21-25% at trough 3
- Avoid nighttime dosing - beta-blockers dosed at night show limited efficacy and may contribute to visual field progression through nocturnal blood pressure reduction 1
- Duration of action extends at least 24 hours even at lower concentrations 4
- Expected IOP reduction: 6-7 mm Hg from baseline (approximately 20-30% reduction) 3
Contraindications
Timolol maleate is absolutely contraindicated in the following conditions: 2
- Bronchial asthma (current or history)
- Severe chronic obstructive pulmonary disease
- Sinus bradycardia
- Second or third degree atrioventricular block
- Overt cardiac failure
- Cardiogenic shock
- Hypersensitivity to any component
Adverse Effects
Ocular Effects
- Burning and stinging on instillation occurs in approximately 1 in 8 patients (12.5%) 2
- Conjunctivitis, blepharitis, keratitis, ocular pain
- Decreased corneal sensitivity
- Dry eyes, foreign body sensation, tearing
- Cystoid macular edema, visual disturbances including refractive changes 2
Cardiovascular Effects (Critical)
Approximately 80% of topically administered timolol is systemically absorbed, bypassing first-pass metabolism, leading to significant systemic effects: 5
- Bradycardia, arrhythmia, heart block
- Hypotension, syncope, cardiac arrest
- Worsening of angina pectoris, cardiac failure
- Pulmonary edema, claudication
- Raynaud's phenomenon, cold hands and feet 2
Respiratory Effects
- Bronchospasm (predominantly in patients with pre-existing bronchospastic disease)
- Respiratory failure, dyspnea, nasal congestion 2
Neuropsychiatric Effects
- Dizziness, depression, confusion, hallucinations
- Anxiety, disorientation, memory loss
- Increase in signs/symptoms of myasthenia gravis
- Nightmares, behavioral changes 2
Metabolic Effects
- Masked symptoms of hypoglycemia in diabetic patients 2
Monitoring Recommendations
Pre-Treatment Assessment
Prior to initiating timolol, perform: 5
- ECG in all patients to identify conduction abnormalities
- Consider CYP2D6 genotyping if available - patients lacking functional CYP2D6 are at high risk for serious cardiac adverse effects 5
- Screen for contraindications, particularly respiratory and cardiac disease
- Baseline IOP measurements (multiple readings to establish mean)
During Treatment
Target IOP should be 20% lower than baseline mean IOP for glaucoma suspects, though higher reductions may be needed if baseline IOP is markedly elevated 1
- Evaluate IOP at each visit and adjust target individually
- Monitor for cardiovascular symptoms (bradycardia, syncope, hypotension)
- Assess for respiratory symptoms, particularly in patients with borderline pulmonary function
- Monitor diabetic patients for hypoglycemic episodes
- Evaluate ocular surface for signs of irritation or inflammation
Critical Drug Interactions
Patients at highest risk for cardiac adverse effects: 5
- Those using potent CYP2D6 inhibitors (paroxetine, fluoxetine)
- Concurrent use of verapamil or other beta-blockers
- These combinations significantly increase plasma timolol levels and cardiovascular toxicity
Clinical Context
Prostaglandin analogs are generally preferred as first-line therapy due to superior efficacy, once-daily dosing, and better tolerability 1. However, timolol remains a commonly prescribed alternative when prostaglandins are contraindicated, not tolerated, or refused by the patient.
Cardioselective beta-blockers (e.g., betaxolol) may be considered in patients with mild obstructive airway disease, though they do not completely eliminate pulmonary risk 1.